Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder
NCT ID: NCT02194075
Last Updated: 2015-10-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
60 participants
INTERVENTIONAL
2013-10-31
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Attention Deficit Disorder Medication Response Study
NCT01727414
Safety and Efficacy of Methylphenidate in Children With Attention-deficit Hyperactivity Disorder (ADHD)
NCT00428792
Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder
NCT00429273
Added Value of the Oculomotor and Cognitive Examination in the Management of Patients With ADHD
NCT03411434
Proton Magnetic Spectroscopy in Children and Adolescents With ADHD Before and After Treatment With OROS Methylphenidate
NCT00593112
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fluvoxamine+Methylphenidate Hydrochloride
Fluvoxamine: tablet, 100mg-300mg/d, were treated with a course of 8 weeks.
Methylphenidate Hydrochloride: tablet, 18mg-36mg/d, were treated with a course of 8 weeks.
Fluvoxamine+Methylphenidate hydrochloride
Fluvoxamine+sugar pill
Fluvoxamine: tablet, 100mg-300mg/d, were treated with a course of 8 weeks.
sugar pill: tablet, 1-2 tablets/d, were treated with a course of 8 weeks.
Fluvoxamine+sugar pill
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fluvoxamine+Methylphenidate hydrochloride
Fluvoxamine+sugar pill
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Met DSM-V criteria
* Y-BOCS ≥ 16
* Course of illness ≥ 1year
* Age range between 18\~40 years old
* Junior high school education level above
Exclusion Criteria
* History of epileptic seizures or any other neurological disorder
* Any other clinically relevant abnormalities in their medical history or laboratory examinations; alcohol or drug abuser
18 Years
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangdong Provincial People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
sunnyrong
MD,PHD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangdong General Hospital, Guangdong academy of medical science
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B2013006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.